A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

Inclusion Criteria:

• Participant is >= 18 years of age at the time of signing the informed consent.

• Participant has a clinical diagnosis of nonsyndromic retinitis pigmentosa.

• Participant is willing to consent to genetic testing, if not already done.

• Cohorts 1 and 2: Participant will have BCVA in the study eye between hand motion and 20 ETDRS letter score (approximately <= 20/400 Snellen equivalent), inclusive atScreening and Baseline.

• Cohort 3: Participant will have BCVA in the study eye between 20 ETDRS letter score (approximately >= 20/400 Snellen equivalent) and 35 ETDRS letter score (approximately <= 20/200 Snellen equivalent), inclusive at Screening.

• Participant is in good physical health, based on medical history, physicalexamination, vital signs, electrocardiogram (ECG), and clinical laboratory tests atScreening.

Exclusion Criteria:

• Participant has an eye disease or visual disorder other than RP that impairs visualfunction (eg, retinal vascular disease, glaucoma).

• Participant has any other eye condition (eg, ocular media opacity, nystagmus), whichin the opinion of the investigator, would preclude an accurate evaluation at anytime during the study and/or make surgical delivery more challenging.

• Participant has any clinically significant unstable medical condition or anyclinically significant chronic disease that in the opinion of the investigator,would limit the participant's ability to complete and/or participate in the study.

• Female participant who is pregnant or lactating or planning to become pregnant.

• Participant has received treatment with any nonapproved, experimental, orinvestigational therapy in either eye (systemic, topical, intravitreal) and/orreceived treatment in an interventional clinical trial for an eye disease ordisorder within 90 days or 5 half-lives, whichever is longer, prior to Screening.

• Participant has previously received cell therapy, gene augmentation therapy, genomeediting therapy, or any subretinal administered therapy for an eye disease ordisorder.